安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42 40 . . .
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD) In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of
- Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer . . .
Objective To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and β-amyloid protein ending at amino acid 42 (Aβ42) as biomarkers for Alzheimer disease (AD) in clinical practice Design A 1-year prospective study Setting Community population–based sample of all consecutive patients admitted for investigation of cognitive symptoms to the Piteå River Valley
- CSF and plasma Aβ42 40 across Alzheimer’s disease continuum: comparison . . .
Objectives Decreased cerebrospinal fluid (CSF) amyloid beta 42 40 ratio (Aβ42 40) is one of the core Alzheimer’s disease (AD) biomarkers Measurement of Aβ42 40 in plasma has also been proposed as a surrogate marker for amyloidosis, however the validity and the diagnostic performance of this biomarker is still uncertain Here we evaluated two immunoassays targeting distinct regions of the
- Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42 Aβ40 . . .
Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42 Aβ40 ratio and total tau The increase in sensitivity, specificity and correct classification of patients when Aβ peptides ratio is applied instead of Aβ42 concentration alone is only a moderate one (e g correct discrimination of AD and controls increases from 86 7 to
- Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary . . .
Area under the curve (AUC) of the p-Tau181 Aβ42 ratio is demonstrated (0 869), as are the specificity (0 889) and sensitivity (0 821) using the assay cutoff of >0 023 Bottom, The AUC, confidence interval, positive and negative predictive values, and sensitivity and specificity of all 4 CSF measures using the current cutoffs
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42 40 Assays in Alzheimer . . .
In BioFINDER, CSF Aβ42 40 was used as the outcome in the main analysis We also performed a sensitivity analysis with Aβ-PET and CSF Aβ42 40 measured with the Euroimmun assay as outcomes to ensure that the results were not biased by the use of the same antibodies in the CSF and plasma for the Elecsys Aβ42 40 assays
- The cerebrospinal fluid biomarker ratio Aβ42 40 identifies amyloid . . .
Limitations include a small sample size, use of a pre-analytical protocol not in accordance with the Elecsys CSF immunoassay method sheets, and the lack of a pre-defined cut-off for Aβ42 40 Point estimates for sensitivity and specificity of CSF biomarkers and biomarker ratios versus amyloid PET were 0 93 and 0 57 for Aβ42, 0 96 and 0 69 for
- CSF and blood biomarkers for the diagnosis of Alzheimers disease: a . . .
Three core CSF biomarkers for the diagnosis of Alzheimer's disease (Aβ42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature 8 High diagnostic accuracy of these biomarkers has been shown for Alzheimer's disease, with sensitivity and specificity reaching 85
|
|
|